 |
| A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo | Novo Nordisk A/S | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Novo Nordisk A/S | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | Novo Nordisk A/S | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Novo Nordisk A/S | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy | Novo Nordisk A/S | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |
| The Role of the Amylin Analogue Cagrilintide in Bone Metabolism | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Novo Nordisk A/S | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Novo Nordisk A/S | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | RenovoRx | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Novo Nordisk A/S | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Novo Nordisk A/S | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity | Novo Nordisk A/S | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |
| A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Novo Nordisk A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Novo Nordisk A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Novo Nordisk A/S | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant | Novo Nordisk A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight | Novo Nordisk A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity | Novo Nordisk A/S | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Novo Nordisk A/S | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Research Study Investigating How Well NDec Works in People With Sickle Cell Disease | Novo Nordisk A/S | NA |
COMPLETED
(Jul 1, 2026)
| PHASE2 |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor | Novo Nordisk A/S | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | Novo Nordisk A/S | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1 |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes | Novo Nordisk A/S | NA |
WITHDRAWN
(Jul 1, 2026)
| PHASE2 |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight | Novo Nordisk A/S | NA |
WITHDRAWN
(Jul 1, 2026)
| PHASE3 |
| A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) | Novo Nordisk A/S | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events | Novo Nordisk A/S | NA |
RECRUITING
(Jun 1, 2026)
| PHASE1 |
| A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Novo Nordisk A/S | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight | Novo Nordisk A/S | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight | Novo Nordisk A/S | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | Novo Nordisk A/S | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |
| A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | Novo Nordisk A/S | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE1 |
| Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Novo Nordisk A/S | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Novo Nordisk A/S | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Novo Nordisk A/S | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Novo Nordisk A/S | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Novo Nordisk A/S | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight | Novo Nordisk A/S | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |
| EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma | NovoCure Ltd. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE2 |
| A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight | Novo Nordisk A/S | NA |
RECRUITING
(Apr 1, 2026)
| PHASE1 |
| A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(Mar 1, 2026)
| PHASE2 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Novo Nordisk A/S | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Novo Nordisk A/S | NA |
NOT YET RECRUITING
(Mar 1, 2026)
| PHASE3 |
| A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Novo Nordisk A/S | NA |
RECRUITING
(Sep, 2024)
| PHASE3 |
| A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice | Novo Nordisk A/S | NA |
COMPLETED
(Sep, 2024)
| |
| Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) | Novo Nordisk A/S | NA |
ACTIVE NOT RECRUITING
(Sep, 2024)
| PHASE3 |
| A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy | Novo Nordisk A/S | NA |
ENROLLING BY INVITATION
(Oct, 2023)
| |
| A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People | Novo Nordisk A/S | NA |
COMPLETED
(Jun, 2023)
| PHASE1 |
| Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(Jul, 2022)
| PHASE3 |
| A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes | Novo Nordisk A/S | NA |
COMPLETED
(Aug, 2018)
| PHASE1 |
